Share Icon Health Study Area: Cardiovascular Disease Chevron Icon Health Study Area: Genitourinary For Patients Health Study Area: Lung Cancer Page Icon Phone Icon For Caregivers Health Study Area: AutoImmune Disease Health Study Area: Melanoma Location Icon Print YouTube Icon For Parents Health Study Area: Lung Cancer Print Created with Sketch. Help Icon Green Check Icon Search Icon Instagram Created with sketchtool. Direction Arrow Icon Error Icon For Parents Health Study Area: Blood Cancer Help Icon Health Study Area: NASH Gender Both Bookmark Icon Health Study Area: Melanoma Created with Sketch. Glossary Print Health Study Area: Blood Cancer Health Study Area: Genitourinary Health Study Area: Gastrointestinal Cancer Mobile Menu Icon Created with Sketch. Health Study Area: Cardiovascular Disease Health Study Area: Women's Cancer Communities Map Icon Created with Sketch. For Caregivers Health Study Area: Fibrosis Health Study Area: AutoImmune Disease FAQs Health Study Area: Head and Neck Cancer Created with Sketch. For Clinicians Chevron Right Icon Gender Female Health Study Area: Breast Cancer Direction Arrow Icon Gender Both Right Arrow Icon LinkedIn Icon Green Check Icon Gender Male Health Study Area: Fibrosis For Patients Twitter Icon Email Icon Facebook Icon Health Study Area: Gastrointestinal Cancer Health Study Area: Head and Neck Cancer For Clinicians External Link Icon
Sök Study Connect
  • NCT06997029

Not Yet Recruiting

A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors - CA243-0001

Uppdaterad: 21 maj, 2025   |   ClinicalTrials.gov

Utskriftsvänlig sammanfattning

ÄR DU INTRESSERAD AV DEN HÄR PRÖVNINGEN?
Skriv ut den här sidan och broschyren om kliniska prövningar som hjälp under samtalet med din läkare.
Använd broschyren ”Om att delta i en klinisk prövning” för att få vägledning om deltagandeprocessen i en klinisk prövning. Förstå de viktiga faktorerna som man måste tänka på före ett beslut och få hjälp med att formulera frågor till studiepersonalen.
Skriv ut den här sidan CA243-0001
Ladda ned broschyren ”Om att delta i en klinisk prövning”

VÄLJ SPRÅK

Information om prövningen

  • Phase 1

    Fas

  • Kön

  • 18+

    Åldersintervall

  • 13

    Platser

  • Not Yet Recruiting

Behandlingsalternativ

Studiegrupper
TILLDELAD BEHANDLING
Experimental: Part 1A Monotherapy Dose Escalation
Drug: BMS-986500
Experimental: Part 1B Combination Dose Escalation
Drug: BMS-986500, Palbociclib, Fulvestrant
Experimental: Part 1C Monotherapy Pharmacodynamic (PD) Sub-study
Drug: BMS-986500
Experimental: Part 2A Monotherapy Dose Expansion
Drug: BMS-986500
Experimental: Part 2B Combination Dose Expansion
Drug: BMS-986500, Palbociclib, Fulvestrant

Viktiga kriterier för deltagandet

Inclusion Criteria: - Participants must be ≥ 18 years of age. - Participants must have histologically confirmed diagnosis of a locally advanced, unresectable, or metastatic solid tumor malignancy. - Participants must have a measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 - Participants must have a stable Eastern Cooperative Oncology Group Performance Status of 0 or 1. - For Part 2A only, participants must have CCNE1-amplified ovarian cancer Exclusion Criteria: - Participants must not have an active brain metastasis. - Participants must not have impaired cardiac function or clinically significant cardiac disease. - Participants must not have bleeding disorder or any history of clinically significant bleeding within the prior 3 months. - Participants must not have Grade ≥ 2 peripheral neuropathy. - Other protocol-defined Inclusion/Exclusion criteria apply.

Vi rekommenderar att du kontaktar BMS för att rapportera biverkningar.
Biverkningar (oönskade händelser) och andra rapporterbara händelser definieras här
För att rapportera biverkningar (oönskade händelser) eller reklamera ett läkemedel: Medicinsk information

466-SE-2100058